Opendata, web and dolomites

MHT-ImmunoEnhancer SIGNED

Stimuli-Responsive Nanoplatform to Combine Magnetic Hyperthermia with Immunemodulators Delivery for Glioblastoma Treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MHT-ImmunoEnhancer project word cloud

Explore the words cloud of the MHT-ImmunoEnhancer project. It provides you a very rough idea of what is the project "MHT-ImmunoEnhancer" about.

survival    thermal    turn    ed    tumour    polymer    responsive    tolerance    release    site    dual    cell    therapies    effectivity    poor    tme    hyperthermia    efficiency    strategy    suppressive    myeloid    nanocubes    immunosuppressive    stimulus    cells    urgent    critical    effect    patient    regression    systemic    ablation    limit    inability    chemotherapy    immunoenhancer    fever    tumours    spreading    intratumoral    iron    limited    untreatable    therapy    immunotherapy    retention    appropriate    therapeutic    chemotherapeutic    glioblastoma    temperature    enzymes    human    establishment    heating    combine    fluorouracil    enhancement    play    mdsc    mht    agent    hybrid    radiotherapy    lethal    surgery    reactivity    microenvironment    magnetic    conventional    overcome    actions    cytotoxic    despite    ph    immune    extremely    induce    improvements    consequently    gbm    ioncs    depletion    immunosupportive    stimuli    prognosis    antitumour    oligonucleotide    fu    treatment    appears    oxide    hyperthermal    local    damage    cpg    context    platforms    mdscs    superior    recurrence    combination    suppressor   

Project "MHT-ImmunoEnhancer" data sheet

The following table provides information about the project.

Coordinator
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA 

Organization address
address: VIA MOREGO 30
city: GENOVA
postcode: 16163
website: www.iit.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 183˙473 €
 EC max contribution 183˙473 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2021-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA IT (GENOVA) coordinator 183˙473.00

Map

 Project objective

Glioblastoma (GBM) is one of the most lethal and untreatable human tumours, and is characterized by its extremely poor prognosis. Conventional therapies, including surgery, radiotherapy and chemotherapy, have not resulted in major improvements in the survival, due to high recurrence and tumour spreading. Therefore, there is an urgent need to develop new effective therapies to improve patient survival. The establishment of an immunosuppressive tumour microenvironment (TME) in GBM is known to limit the cytotoxic effects of conventional therapies and in this context, myeloid-derived suppressor cells (MDSCs) play a critical role by promoting immune tolerance, tumour growth and spreading. Hyperthermal therapy in GBM has resulted in improved immune reactivity of tumours, despite this, its effectivity has been limited by its inability to overcome the immunosuppressive TME and induce strong systemic antitumour responses. Consequently, targeting MDSCs in combination with thermal ablation therapies appears to be a very promising strategy. The goal of the MHT-ImmunoEnhancer project is the development of a dual stimuli-responsive hybrid polymer/Iron oxide nanocubes (IONCs) delivery system in order to combine local fever-range Magnetic Hyperthermia (MHT) with MDSC depletion-targeted immunotherapy for intratumoral treatment of GBM. The specific objectives of our strategy are, 1) to exploit the superior heating efficiency of the hybrid polymer/IONCs platforms to induce tumour damage. 2) To turn the immunosuppressive TME into an immunosupportive one, by local delivery of CpG oligonucleotide; along with 5-Fluorouracil (5-FU), a chemotherapeutic agent. 3) To release CpG and 5-FU specifically at the tumour site under the appropriate stimulus (pH or enzymes/temperature), thus enhancing their tumour retention and therapeutic effect. All these actions will result in the reduction of T-cell-suppressive activity of MDSCs, enhancement of antitumour immune response and tumour regression.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MHT-IMMUNOENHANCER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MHT-IMMUNOENHANCER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EPIC (2019)

Evolution of Planktonic Gastropod Calcification

Read More  

FOCUSIS (2020)

Focal volume Control Using Structured Illumination Sources

Read More  

MarshFlux (2020)

The effect of future global climate and land-use change on greenhouse gas fluxes and microbial processes in salt marshes

Read More